HealthCare Global Enterprises Ltd

HCG Reports Strong FY26 Growth: Revenue Up 15%, EBITDA Margin Hits 18.5% 📈

- Revenue from operations for Q4FY26 was Rs. 6,523 Mn, up 11% YoY; FY26 revenue was Rs. 25,454 Mn, up 15% YoY.

- Adjusted EBITDA for Q4FY26 was Rs. 1,252 Mn, up 17% YoY; FY26 EBITDA was Rs. 4,711 Mn, up 19% YoY.

- Adjusted PAT for Q4FY26 was Rs. 341 Mn, up 363% YoY; FY26 PAT was Rs. 557 Mn, up 25% YoY.

- HCG's EBITDA margin improved to 19.2% in Q4FY26 and 18.5% in FY26, reflecting operational efficiency.

- Dr. B. S. Ajaikumar highlighted HCG's focus on early diagnosis, precision medicine, and personalized cancer care.

- Dr. Manish Mattoo emphasized HCG's strong execution, with growth driven by improved capacity utilization and cost management.

- HCG completed a Rs. 4,250 Mn rights issue to fund expansion, technology upgrades, and clinical infrastructure.

- HCG operates 25 hospitals across India and Africa, providing comprehensive cancer care services.